Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 6, 2012, Pages 1496-1502

  Stryjewski, Martin E ^a,b   Barriere, Steven L ^c   O'Riordan, William ^d   Dunbar, Lala M ^e   Hopkins, Alan ^c   Genter, Fredric C ^c   Corey, G Ralph ^b  

^a CEMIC   (Argentina)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c THERAVANCE INC   (United States)

^d Study Site   (United States)

^e LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Abscess; Cellulitis; MRSA; Panton Valentine leucocidin

Indexed keywords

PANTON VALENTINE LEUKOCIDIN; TELAVANCIN; VANCOMYCIN;

ADULT; ARTICLE; BACTERIAL SKIN DISEASE; BURN INFECTION; CELLULITIS; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; FATIGUE; FEMALE; HEADACHE; HUMAN; INJECTION SITE PAIN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRURITUS; RASH; RIGOR; SKIN ABSCESS; TASTE DISORDER; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE; WOUND INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; EXOTOXINS; FEMALE; HUMANS; LEUKOCIDINS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STAPHYLOCOCCAL SKIN INFECTIONS; TREATMENT OUTCOME; UNITED STATES; VIRULENCE FACTORS; YOUNG ADULT;

EID: 84861165496     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks081     Document Type: Article

References (32)

1. Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46 Suppl 5: S344-9.
2. Klevens RM, Morrison MA, Nadle J et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298: 1763-71.
3. Moran GJ, Krishnadasan A, Gorwitz RJ et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355: 666-74.
4. Rosenthal VD, Maki DG, Mehta A et al. International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control 2008; 36: 627-37.
5. Gagliotti C, Balode A, Baquero F et al. Escherichia coli and Staphylococcus aureus: bad news and good news from the European Antimicrobial Resistance Surveillance Network (EARS-Net, formerly EARSS), 2002 to 2009. Euro Surveill 2011; 16: pii=19819.
6. Burton DC, Edwards JR, Horan TC et al. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA 2009; 301: 727-36.
7. de Kraker ME, Wolkewitz M, Davey PG et al. Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother 2011; 55: 1598-605.
8. King MD, Humphrey BJ, Wang YF et al. Emergence of communityacquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006; 144: 309-17.
9. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46 Suppl 5: S368-77.
10. Deresinski S. Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus. J Infect Dis 2009; 199: 605-9.
11. Smith TL, Pearson ML, Wilcox KR et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999; 340: 493-501.
12. Tenover FC. Vancomycin-resistant Staphylococcus aureus: a perfect but geographically limited storm? Clin Infect Dis 2008; 46: 675-7.
13. Kirby A, Graham R, Williams NJ et al. Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK. J Antimicrob Chemother 2010; 65: 721-4.
14. Wang G, Hindler JF, Ward KW et al. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006; 44: 3883-6.
15. Witte W, Cuny C. Emergence and spread of cfr-mediated multiresistance in staphylococci: an interdisciplinary challenge. Future Microbiol 2011; 6: 925-31.
16. van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-nai{dotless}̈ve patient2a review of the literature. Eur J Clin Microbiol Infect Dis 2011; 30: 603-10.
17. Higgins DL, Chang R, Debabov DV et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 1127-34.
18. Nannini EC, Stryjewski ME. A new lipoglycopeptide: telavancin. Expert Opin Pharmacother 2008; 9: 2197-207.
19. Barcia-Macay M, Lemaire S, Mingeot-Leclercq MPet al. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillinresistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58: 1177-84.
20. Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58: 338-43.
21. Madrigal AG, Basuino L, Chambers HF. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 3163-5.
22. Stryjewski ME, Graham DR, Wilson SE et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin Infect Dis 2008; 46: 1683-93.
23. Wilson SE, O'Riordan W, Hopkins A et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. Am J Surg 2009; 197: 791-6.
24. Agresti A, Caffo B. Simple and effective confidence intervals for proportions and differences of proportions result from adding two successes and two failures. Am Stat 2000; 54: 280-8.
25. Llera JL, Levy RC. Treatment of cutaneous abscess: a double-blind clinical study. Ann Emerg Med 1985; 14: 15-9.
26. Lee MC, Rios AM, Aten MF et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2004; 23: 123-7.
27. Rajendran PM, Young D, Maurer T et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2007; 51: 4044-8.
28. Ruhe JJ, Smith N, Bradsher RW et al. Community-onset methicillinresistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis 2007; 44: 777-84.
29. Ellis Simonsen SM, van Orman ER, Hatch BE et al. Cellulitis incidence in a defined population. Epidemiol Infect 2006; 134: 293-9.
30. McCaig LF, McDonald LC, Mandal S et al. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis 2006; 12: 1715-23.
31. Bae IG, Tonthat GT, Stryjewski ME et al. Presence of genes encoding the Panton-Valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial. J Clin Microbiol 2009; 47: 3952-7.
32. Carleton HA, Diep BA, Charlebois ED et al. Community-adapted methicillin-resistant Staphylococcus aureus (MRSA): population dynamics of an expanding community reservoir of MRSA. J Infect Dis 2004; 190: 1730-8.